Mitochondrial Disease-associated ImmunoDeficiencies — MitoID  

Mitochondrial Disorders Clinical Trial

Official title: Determining the Relevance of Mitochondrial Disease-associated ImmunoDeficiencies - MitoID

Status Recruiting

Clinical Trial Summary

The study aims at characterizing the immune dysfunctions in patients with mitochondrial diseases. This has prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies to alleviate disease burden.

Clinical Trial Description

Mitochondrial pathologies are rare genetic diseases, and affect about 1 in 4300 people. These pathologies are characterized by an energetic deficit that can affect all organs, and can manifest from birth to adulthood. The clinical expression is very heterogeneous, the symptoms can include encephalopathies, myopathies, cardiomyopathies, among others, with frequently "an illegitimate association of symptoms" that add up in a progressive way. These pathologies are related to the presence of pathogenic mutations in the genes of the nuclear genome involved in mitochondrial metabolism, or directly in the genes of the mitochondrial DNA (mtDNA). The immune system dysfunctions associated with mitochondrial diseases remain unknown to date despite the presence of the deleterious variant in leukocytes. Recent studies by group of the investigators and others in animal models clearly show the importance of mitochondrial functions in the regulation of inflammatory and antimicrobial processes. These experimental data are particularly relevant in light of recent clinical studies indicating that patients with mitochondriopathies have a higher rate of bacterial infections compared to control individuals. The investigators hypothesized that immunological parameters assessment in patients will reveal new dysfunctions associated with these pathologies and that some of these parameters will be a prognostic factor in these "step-like" progression of these diseases. This study will recruit 30 patients with mitochondrial disorders followed in Bordeaux University Hospital and Toulouse University Hospital for who the mutation of mitochondrial DNA has been previously identified. Among classical disease activity information, blood samples will be collected to study immunological parameters. Translational research will be realized on patient' samples to assess immune cell subsets and innate immune cells functions. ;

Related Conditions & MeSH terms

• Mitochondrial Diseases
• Mitochondrial Disorders

• NCT number: NCT06213103
• Study type: Observational
• Source: University Hospital, Bordeaux
• Contact: Aurélien TRIMOUILLE, MD
• Phone: +335 57 82 10 49
• Email: aurelien.trimouille@chu-bordeaux.fr
• Status: Recruiting
• Start date: January 30, 2024
• Completion date: January 2025